Porvenir · Accessibility Design for Pharmaceutical & Biotech Companies
Accessibility Design
for
Pharmaceutical & Biotech Companies.
Accessible design is not a compliance checkbox — it is better design for every user. We audit and redesign digital products to meet WCAG 2.1 AA and AAA standards — making products legally compliant, ethically sound, and genuinely usable by the widest possible audience.
Specialised for pharmaceutical & biotech companies. Pharmaceutical and biotech companies must build scientific credibility and investor confidence simultaneously.
What pharmaceutical & biotech companies search for
accessible UX design agency for pharmaceutical & biotech companies — that is exactly what we deliver.
How we deliver accessibility design for pharmaceutical & biotech companies
A process built for
pharmaceutical & biotech companies.
Accessibility audit — automated and manual testing against WCAG 2.1 success criteria
User testing — testing with users who rely on assistive technology
Remediation design — redesigning failing components with fully accessible alternatives
Developer handoff — ARIA specifications, semantic HTML requirements, and focus management guidelines
What pharmaceutical & biotech companies gain
Real business outcomes
for pharmaceutical & biotech companies.
WCAG 2.1 AA compliance that passes enterprise and government procurement accessibility review
Elimination of legal liability from accessibility discrimination claims
A more usable product for every user, including those without disabilities
Why pharmaceutical & biotech companies invest in accessibility design
The problems we solve
for pharmaceutical & biotech companies.
Where we work
Serving pharmaceutical & biotech companies globally.
Other Product Design services for pharmaceutical & biotech companies
Accessibility Design for Pharmaceutical & Biotech Companies
Ready to generate more
leads for your pharmaceutical & biotech?
Book a discovery call. No pitch, no pressure — just a focused conversation about where you are and where you want to be.